Mon, June 24, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, June 18, 2024
[ 12:00 AM ] - WOPRAI
Fri, June 14, 2024
[ 12:00 AM ] - WOPRAI
Wed, March 27, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, January 31, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, November 3, 2023
[ 12:00 AM ] - WOPRAI
Tue, October 10, 2023
[ 12:00 AM ] - WOPRAI
Wed, July 5, 2023
[ 12:00 AM ] - WOPRAI
Fri, May 5, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 7, 2023
[ 12:00 AM ] - WOPRAI
Mon, January 30, 2023
[ 12:00 AM ] - WOPRAI
Tue, December 20, 2022
[ 12:00 AM ] - WOPRAI
Mon, July 18, 2022
[ 12:00 AM ] - WOPRAI
Fri, June 17, 2022
[ 12:00 AM ] - WOPRAI
Kostas Biliouris Maintained (SRPT) at Buy with Increased Target to $200 on, Jun 24th, 2024
Kostas Biliouris of BMO Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $170 to $200 on, Jun 24th, 2024.
Kostas has made no other calls on SRPT in the last 4 months.
There are 12 other peers that have a rating on SRPT. Out of the 12 peers that are also analyzing SRPT, 2 agree with Kostas's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $182 on, Friday, June 21st, 2024
- Kristen Kluska of "Cantor Fitzgerald" Reiterated at Hold and Held Target at $128 on, Friday, June 21st, 2024
These are the ratings of the 10 analyists that currently disagree with Kostas
- Biren Amin of "Piper Sandler" Maintained at Buy and Held Target at $157 on, Friday, June 21st, 2024
- Brian Skorney of "Baird" Maintained at Buy with Increased Target to $200 on, Friday, June 21st, 2024
- Gena Wang of "Barclays" Maintained at Buy with Increased Target to $226 on, Friday, June 21st, 2024
- Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $235 on, Friday, June 21st, 2024
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $213 on, Friday, June 21st, 2024
- Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $179 on, Friday, May 17th, 2024
- Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $180 on, Tuesday, May 14th, 2024
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $175 on, Friday, May 3rd, 2024
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $167 on, Friday, March 1st, 2024
- David Hoang of "Citigroup" Maintained at Strong Buy with Increased Target to $172 on, Thursday, February 29th, 2024
Contributing Sources